This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners
by Sanghamitra Saha
Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.
Pharma ETFs Gain on Healthy Q4 Earnings
by Sweta Killa
Strong results led to solid trading in pharma ETFs over the past week.
Biotech Rally Sends Nasdaq to 9000: ETFs in Focus
by Sanghamitra Saha
Some biotech stocks have contributed materially to the Nasdaq's 1000-point gain since Aug 27, 2018 and helped it notch a record 9,000 on Dec 26.
4 Sector ETFs That Beat the Market in Q4
by Sanghamitra Saha
While Wall Street is surging this quarter, these sector ETFs offered even better performances to beat the market.
Pharma Sector Tops in October: Best ETFs & Stocks
by Sanghamitra Saha
Pharma sector wins in October, making these ETFs and stocks winners.
Pharma ETFs Set to Benefit Post Strong Q3 Earnings
by Sweta Killa
Robust results led to solid trading in pharma ETFs in a month.
Healthcare ETFs Win in October: Here's Why
by Sweta Killa
The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.
Pharma Q2 Earnings Growth Highest: Time to Buy ETFs?
by Sweta Killa
Despite robust results, pharma ETFs have been trending downward in a month.
AbbVie to Buy Allergan: Prescribed ETFs
by Sweta Killa
AbbVie has agreed to buy Botox-maker Allergan for $63 billion in a cash-and-stock deal. The news has put the spotlight on a number of healthcare ETFs.
Pharma ETFs Down Despite Solid Q1 Results
by Sweta Killa
Despite such robust results, pharma ETFs have been trending downward in a month.